Drug resistance and its significance for treatment decisions in non-small-cell lung cancer

Current Oncology

Volumn 19, Issue S1, 2012, Pages S45-S51

  Tsvetkova, E ^a   Goss, G D ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Nsclc; Primary resistance; Secondary resistance

Indexed keywords

EID: 84891661874     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1113     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society; 2011.
3. Travis WD. Pathology of lung cancer. Clin Chest Med 2002;23:65-81.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
5. Lagunas VM, Meléndez-Zajgla J. Nuclear factor-κB as a resistance factor to platinum-based antineoplastic drugs. Met Based Drugs 2008;2008:576104.
6. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
7. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26:71-83.
8. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
9. Mountzios G, Dimopoulos MA, Papadimitriou C. Excision repair cross-complementation group 1 enzyme as a molecular determinant of responsiveness to platinum-based chemotherapy for non small-cell lung cancer. Biomark Insights 2008;3:219-26.
10. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007;13:284-9.
11. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-7.
12. Olaussen KA, Dunant A, Fouret P, et al. dna repair by ercc1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
13. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010;67:101-7.
14. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubuleinterfering agents, an effect that involves the Jnk pathway. Oncogene 2001;20:6597-606.
15. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-3.
16. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the dna cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
17. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-31.
18. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
19. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5:1001-7.
20. Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mrna expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008;8:97.
21. Taron M, Rosell R, Felip E, et al. BRCA1 mrna expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13:2443-9.
22. Quinn JE, James CR, Stewart GE, et al. BRCA1 mrna expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-20.
23. Harper JW, Elledge SJ. The dna damage response: Ten years after. Mol Cell 2007;28:739-45.
24. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and Rap80 form a BRCA1 protein complex required for the dna damage response. Science 2007;316:1194-8.
25. Sobhian B, Shao G, Lilli DR, et al. Rap80 targets brca1 to specific ubiquitin structures at dna damage sites. Science 2007;316:1198-202.
26. Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 2007;27:1449-52.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
28. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
29. Sos ML, Koker M, Weir BA, et al. pten loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and egfr. Cancer Res 2009;69:3256-61.
30. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
32. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
33. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
34. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
35. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-ras mutations as a mechanism associated with resistance to egfr-targeted agents: A systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
36. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8.
37. Prudkin L, Tang X, Wistuba II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 2009;4:139-41.
38. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87.
39. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
40. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
41. Sos ML, Zander T, Thomas RK, Staratschek-Jox A, Claasen J, Wolf J. Expression of signaling mediators downstream of egf-receptor predict sensitivity to small molecule inhibitors directed against the egf-receptor pathway. J Thorac Oncol 2008;3:170-3.
42. Semrad TJ, Mack PC. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer 2012;13:90-5.
43. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
44. Husain H, Rudin CM. Alk-targeted therapy for lung cancer: Ready for prime time. Oncology (Williston Park) 2011;25:597-601.
45. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
46. Griffiths MJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet 2005;366:249-60.
47. Kiesslich T, Neureiter D. Advances in targeting the Hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:151-6.
48. Mimeault M, Batra SK. Frequent deregulations in the Hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010;62:497-524.
49. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: Evidence of Dishevelled overexpression. Oncogene 2003;22:7218-21.
50. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (ipass). J Clin Oncol 2011;29:2866-74.